Comparative

Human disease

alopecia universalis congenita

MONDO:0008757

Mondo defines it as: “The most severe form of alopecia areata, an inflammatory disease of the hair follicle, which is characterized by a complete loss of hair of the scalp and all the hair-bearing areas of the body.”

3 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
2229 Hypotrichosis, HR-related OMIA's OMIM numbers 10 Target evidence 78.7
30 Alopecia, generic OMIA's OMIM numbers 9 Human disease 35.0
1278 Hypotrichosis, dominant OMIA's OMIM numbers 2 Human disease 32.0

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Human gene Score Evidence
HR 0.76 299

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Methotrexate None of these genes Phase 3
Prednisone None of these genes Phase 3
Tofacitinib None of these genes Phase 3
Botulinum Toxin Type A None of these genes Phase 2/3
Letibotulinumtoxina None of these genes Phase 2/3
Onabotulinumtoxina None of these genes Phase 2/3
Abatacept None of these genes Phase 2
Azathioprine None of these genes Phase 2
Betamethasone None of these genes Phase 2
Efalizumab None of these genes Phase 2
Ifidancitinib None of these genes Phase 2
Minoxidil None of these genes Phase 2
Betamethasone Valerate None of these genes Phase 1
Metformin None of these genes Phase 1
Pentoxifylline None of these genes Phase 1
Apremilast None of these genes Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.